Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined whether gut microbial dysbiosis contributes to immune dysregulation complications (CVIDid) in common variable immunodeficiency, a condition affecting roughly a third of CVID patients. They compared colon biopsies and fecal microbiota across CVID with immune dysregulation, CVID with infections only, X-linked agammaglobulinemia, and healthy controls.
How was it studied?
Colon biopsies from 15 CVID, 3 XLA, and 9 healthy control patients were stained for bacteria and IgA. Fecal microbiota from 42 CVIDid, 51 CVIDio, 40 CVID-IgA-deficient, and 48 healthy control samples was profiled with 16S rRNA amplicon sequencing, and Enterococcus strains were tested in monocyte cocultures.
What did they find?
Bacteria invaded colonic crypts in 3 of 15 CVID and 1 of 3 XLA biopsies, but none of 9 controls. CVIDid and CVID-IgA groups showed increased bacterial load, lower alpha diversity, and enrichment of Enterococcus, and Enterococcus gallinarum and Enterococcus hirae triggered inflammatory responses in patient monocytes.
Why it matters
The findings identify enterococci as candidate pathobionts and IgA deficiency as a likely driver of gut dysbiosis and systemic inflammation in CVID, suggesting gut pathobionts as a possible future therapeutic target.